Overview

Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease

Status:
Approved for marketing

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific adult patients with Fabry disease. Treatment is open label for 6 months with renewal every 6 months.

Details

Lead Sponsor:

Amicus Therapeutics